Summary. Studies of immunoreaetive insulin (IRI) secretion have been performed in vivo in NZO mice. After an overnight fast, plasma IgI levels were 2--5 ~imes higher in NZO than in control white mice. The It~I response to arginine, 10 mg/kg IV or isoprenaline, 10 ~g/kg IV, was similar in time in the two mice, but IgI increments were greater in the NZO animals. With glueagon 1 ~g/kg IV or aminophylline 25 mg/kg IV the initial secretory response was delayed compared to control mice. Glucose 1.0 g/kg IV elicited a markedly attenuated initial response in NZO mice. When IRI responses were related to basal IRI levels, NZO mice showed smaller initial responses (1--5 rain) to all agents tested. Later responses were comparable in the two groups when compared in this way. Diphe~ylhydantoin, 40 mg/kg administered intraperitoneally 30 rain before glucose, 1.0 g/kg IV did not affect glucose-induced insulin secretion in control animals, but abolished it. in the NZO mice. These observations suggest the existence of a defect in the 11%1 release mechanism of the NZO fl cell situated at a point in the stimulus secretion coupling" mechanism common to all the agents examined.
Introduction
The syndrome of obesity and hyperglycemia in NZO mice originally described by Bielschowsky and Bielsehowsky [2] is eharaeterised by hyperinsulinemia and increased pancreatic insulin stores [17, 18] . Larkins and Martin [12] reported that glucose, glucagon and tolbutamide, administered intraperitoneally (IP), did not stimulate release of insulin in rive while arginine was able to do so. Because of the important implications of these observations in relation to the hyperinsulinemia of obesity and ~he regulation of insulin secretion in general, these studies were undertaken using methods previously employed for in rive studies of insulin secretion in rodents [3, 4, 5] 
Materials and Methods
Animals NZO mice from the colony maintained at Prince Henry's Hospital, Melbourne, were used. The progenitors were obtained as a gift from Dr. M. I-Iolmes, Walter and Eliza Hall Institute, Melbourne. Control mice were random-bred white mice from the Prince Henry's Hospital colony and were originally derived from a colony at the Commonwealth Serum Laboratories, Parkville, Victoria. All animals were maintained under standard conditions of lighting, temperature and humidity and fed a commercial chow ad lib. Animals were between 4 and 8 months old at the time of study.
Experimental Procedures
Animals were fasted overnight and anesthetised with pentobarbitone sodium (60 ~g/kg, IP, and 30 ~g/kg subcutaneously). Insulin secretion was studied in response to glucose, 1.0 g/kg, arginine, 10 mg/kg, glucagon, 1 ~g/kg, aminophylline, 25 mg/kg and isoprenaline, 10 ~g/kg administered as bolus injections into a tail vein. In one experiment, diphenylhydantoin (DPH), 40 mg/kg was administered IP 30 rain before the intravenous injection of glucose. Blood samples were collected from the retro-orbital plexus into heparinised hematocrit tubes, transferred immediately to iced mierofuge tubes, centrifuged and the plasma stored at --16~ until assayed.
Assay Procedures
Plasma glucose was determined by a glucose oxidase method [1] on 5 y.1 aliquots of plasma as described previously [4] . Plasma immunoreaetive insulin (IRI) was assayed by the method previously reported [4] with the following modification. At the time of addition of the second antibody, 10 ~l of human plasma from which the insulin had been "stripped" by incubation with activated charcoal, was added to the standard curve tubes. This resulted in an equal concentration of plasma in all assay tubes.
Reagents and Chemicals
The mouse insulin standard used in the radioimmunoassay was a gift from Dr . 1 shows the response of plasma II~I to glucose 1.0 g/kg IV. Initial plasma IRI is higher in NZO than control mice. After glucose administration, the control
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In contrast with the impaired initial response to glucose, NZO mice respond to arginine ( Fig. 2) with an immediate release of insulin which is quantitatively greater than in the controls. With administration of isoprenaline also (I~ig. 3), IRI release in NZO mice is similar in time compared to controls reaching both peak plasma values at 5 rain. Quantitatively, NZO mice release greater amounts of insulin than do controls.
With both glueagon (Fig. 4) and aminophylline ( Fig. 5 ) administration, a delayed initial release is observed in NZO compared to white mice. Thus, the peak plasma II~I levels are seen at 5 .min in NZO mice respond with an immediate, marked release of insulin. The NZO mice in contrast have a lesser initial response and at one minute, the plasma IgI levels are significantly higher in the control mice (20 < 0.05). Plasma IgI levels progressively decline in NZO mice after the initial response while in NZO animals the elevation of plasma It~I is maintained for at least two hours. This occurs despite the fact that plasma glucose levels are not significantly different in the two groups at this time.
control mice: Plasma II~I and glucose levels. (Meani  SEM) animals while in the controls an immediate shortlived response is seen with the one minute values being the highest. After aminophylline, the plasma IRI levels in NZO mice remain substantially elevated above basal throughout the study.
In Table l , the responses of plasma Ii~I to the various test agents are compared as percentage elevations above basal (taken as 100%). When expressed in this manner, it is evident that the initial insulin release is deficient in the NZO mice in response to all the agents while later release is comparable in the two groups. 6 shows the results of an experiment in which DPtt was administered IP 30 min before glucose, 1.0 g/kg IV. Following DPH, plasma IgI rose in both NZO and control mice. Glucose induced 11%1 release was unaffected in the controls but was abolished in the NZO animals.
Discussion
These studies present further evidence for a defective insulin secretory mechanism in the inbred mouse strain NZO. The abnormalities of fl-cell function insulin. The present results, while confirming the presence of defective insulin release to a variety of known insulin secretagogues suggest that there is a relative, not an absolute, inability on the part of these agents to cause insulin relase. The reasons for the differences between Larkins and Martin's results and those in the present study may relate to the differences in experimental protocols especially in the route of administration of the test substances.
Relatively few kinetic studies of insulin release in vivo in obese hyperglycemic rodents have been published [3, 4, 5, 12, 21] . In obob mutants and DBM mice before they become grossly hyperglycemic, it in this strain appear to be twofold. First, basal insulin secretion is elevated. In the present study, fasting plasma IRI values in NZO mice were two to five times greater than in controls. Second, the ability of the fi-cells to respond rapidly to an acute insnlinotropic stimulus appears impaired. Elevated plasma IRI levels in NZO mice have been reported by Sneyd [17] and by Stauffacher et al. [18] as well as by Larkins and Martin [12] . The latter authors have reported the only kinetic studies to date on IRI release in this strain. They found that glucose, glucagon and tolbutamide administered IP all failed to elicit IRI release. Arginine, however, caused marked release of was considered [3, 4, 21] that IRI release was quantitatively excessive though temporally normal. The same applied to the induced syndrome of goldthioglucose obesity [3, 4] . However, on re-examination of the data, if these responses are considered in relation to the basal Ii~I levels, insulin responses to stimuli may be considered deficient in all these syndromes.
The acomys cahirinus appears to have a generalised defect of insulin secretion [3, 5] : despite the presence of obesity, basal plasma IRI levels are low and IRI release is deficient in both absolute and relative terms. [18] have presented evidence for a relative insulin resistance in the muscle tissues of this strain and have suggested that hyperinsulinemia may be a compensatory phenomenon.
Gates et al. [9] on the other hand have shown that the implantation of islets derived from normal mice into NZO animals results in a decrease in plasma insulin levels in the recipients. They have suggested that the NZO strain lacks a pancreatic factor normally acting to inhibit insulin secretion. The effectiveness of arginine as an insulin secretagogue in NZO mice may be relevant since Felig et al. [8] have demonstrated raised levels of certain amino acids in the plasma of greater IRI release in NZO mice than controls while the temporal pattern is the same as in control animals. By contrast, initial IRI release with glucose is deficient in NZO mice in absolute as well as relative terms. With glucagon or aminophylline, initial release appears delayed in the NZO animals with peak values being seen at 5 min compared with one minute in controls. It is possible that with these agents the true peak occurred between one and 5 rain and was therefore not detected. It seems probable that a defect exists in the final common pathway of release for all stimuli. This could be related to either the storage or release of insulin. It has been suggested that different insulin secretagogues may cause release from different "pools" within the fi-eell [22] . In addition, it is possible Control  100  732  2536  465  366  NZO  100  i84  605  234  171  Aminophylline,  25 mg/kg IV  Control  100  525  183  146  100  NZO  100  327  404  288  327   238  215  232 obese humans. Data on the plasma amino acid levels in NZO mice are not available. Islet mass and pancreatic insulin content are known to be elevated in NZO mice [18] . However, it is not clear whether the elevated basal insulin levels stem from an increased number of #-cells all secreting at a normal rate, or if the individual /+-cells have an increased rate of secretion. Such information may aid in the understanding of the impaired acute insulin release seen after administration of various secretagogues.
The analysis of the data as presented in Table 1 indicates that, relative to the basal levels of Ii~I, the initial release of insulin is defective with all the agents studied. However, it is evident that the response to some agents is more markedly affected than to others. In absolute terms, arginine and isoprenaline cause that abnormalities occur on the stimulus side of the stimulus secretion coupling mechanism, since the various secretagogues are affected to different degrees. For instance, arginine is more effective both in absolute and relative terms than glucose when compared to the response in control mice. Glucagon, isoprenaline and aminophylline are considered to stimulate insulin secretion by increasing fl-cell cyclic AMP levels and the adenyl eyclase system is considered to be an important component of the mechanism whereby glucose causes insulin release [10, 14, 16, 19, 20] . Gates et at. [9] have reported that adenyl cyclase activity is the same in isolated islets of NZO mice and control mice after incubation with glucose, glucagon or tolbutamide. This could imply that the defect in initial insulin release lies beyond the generation of cyclic AMP or that other, noncyclic AMP dependent mechanisms are abnormal in NZO mice.
Larkins [11] has reported studies of IgI release in isolated islets of NZO mice. These studie.s showed responses similar to those observed in vivo. Basal insulin secretion was greater from NZO islets. The threshold for a significant release of insulin with glucose was higher in NZO mice than controls and there was a delayed pattern of release. Glueagon and tolbutamide failed to elicit a response in NZO mice at has been reported to inhibit glucose induced IRI release to a greater degree than in normal controls [13] . The basis of its action is unclear; however, it may interfere with an already defective receptor mechanism for glucose. It appears that further studies of insulin secretion in NZO mice are indicated, since an understanding of the basis for the observed abnormalities may be an important step in the study of the control of insulin secretion in maturity onset diabetes. concentrations which were effective in control animals, whereas NZO islets were more sensitive to arginine. It was further shown that the response to glucose in NZO mice was greatly increased by theophylline. Despite the demonstration of these abnormalities in vitro, it remains uncertain as to whether they represent primary defects within the fi-cell or are secondary to some longstanding metabolic abnormality in viva. NZ0 mice therefore exhibit certain characteristics of insulin secretion which are comparable to those seen in human obese diabetics. The basal levels of plasma IRI are elevated and the early phase of IRI release, is diminished and/or delayed. Later phase insulin release and therefore total insulin released, is excessive in absolute terms. The effect of DPH is also similar to that seen in obese humans where it 
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